Aliyev M. H., Khalilov F. F.

MICROBIOTA OF THE RESPIRATORY TRACT IN PATIENTS WITH BREAST CANCER ASSOCIATED WITH INFECTIOUS-INFLAMMATORY COMPLICATIONS

---

Show/Download

About the author:

Aliyev M. H., Khalilov F. F.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The toxic-allergic side effects of chemotherapy on tissues of various organs and body systems, including the gastrointestinal tract microflora, lead to significant problems associated with an increased incidence of serious complications in most patients with cancer. The study was conducted to investigate changes in the respiratory system microflora during the development of infectious-inflammatory complications in patients with breast cancer. Sputum secreted by patients was examined to determine the characteristic features and differences in the upper respiratory tract microflora in 22 patients in the main group with breast cancer associated with respiratory pathology, 20 patients in the comparison group without such concomitant pathological changes, and 10 practically healthy individuals in the control group without cancer. In the microbial landscape of the examined patients of this group, gram-positive microorganisms of the genus Streptococcus spp. prevailed, in particular, Streptococcus pyogenes, the specific gravity of which was 25.0%. Among the gram-negative pathogens in the studied biological environment, Escherichia coli prevailed, and among the representatives of the fungal microflora, high rates of seeding frequency belonged to C. albicans. In the microflora of the respiratory tract of patients with breast cancer and without respiratory complications, that is, in the comparison group, an increase in the frequency of detection of strains of gram-positive flora due to their representative of the species Staphylococcus aureus was initially observed. An increase in the specific gravity of mainly gram-negative microflora and Candida fungi was noted in the microbiocenosis of patients who made up the main group. It is also important to note that the rates of Klebsiella pneumoniae isolation from the oropharynx of patients in the main group were the highest when compared with the data from the other two groups.

Tags:

Bibliography:

1. Guo L, Kong D, Liu J, Ling Z, Lan L, Weijie Z, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12:3. DOI: https://doi.org/10.1186/s40164-022-00363-1.
2. Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, et al. Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. Biomed Res Int. 2022;2022:9605439. DOI: 10.1155/2022/9605439.
3. Sparano JA, Gray RJ, Ravdin PM, Ravdin PM, Makower DF, Pritchard KI, et al.: Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019;380(25):2395-2405.
4. Barber LE, Maliniak ML, Moubadder L, Johnson DA, Miller-Kleinhenz JM, Switchenkoet JM, et al. Neighborhood deprivation and breast cancer mortality among black and white women. JAMA Oncol. 2024;7(6):e2416499. DOI: 10.1001/jamanetworkopen.2024.16499.
5. American cancer society. Breast cancer statistics: how common is breast cancer? Atlanta: American cancer society; 2024. Available from: https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html#:~:text=50%20(1.0%25)-.
6. Contiero P, Boffi R, Borgini A, Fabiano S, Tittarelli A, Mian M, et al. Causes of death in women with breast cancer: a risks and rates study on a population-based cohort. Front Oncol. 2023;13:1270877. DOI: 10.3389/fonc.2023.1270877.
7. Riggan KA, Rousseau A, Halyard MY, James E, Kelly M, Phillips D, et al. “There’s not enough studies”: Views of black breast and ovarian cancer patients on research participation. Cancer Medicine. 2023;12(7)1-10. DOI: doi.org/10.1002/cam4.5622.
8. American Cancer Society. Breast Cancer Facts & Figures 2022-2024. Atlanta: American Cancer Society; 2022.
9. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021;13(17):4287. DOI: 10.3390/cancers13174287.
10. Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J. Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. Cancer Epidemiol Biomarkers Prev. 2019;28(5):835-845. DOI: 10.1158/1055-9965.
11. Jenkins S, Kachur ME, Rechache K, Wells JM, Lipkowitz S. Rare Breast Cancer Subtypes. Curr Oncol Rep. 2021;23(5):54. DOI: 10.1007/ s11912-021-01048-4.
12. Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022;155:131- 166. DOI: 10.1016/bs.acr.2022.02.007.
13. Galateanu B, Pușcașu AI, Tircol SA, Tanase BC, Hudita A, Negrei C, et al. Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions. Int J Mol Sci. 2023;24(4):3886. DOI: 10.3390/ijms24043886.
14. van den Boogaard WMC, Komninos DSJ, Vermeij WP. Chemotherapy Side-Effects: Not All DNA Damage Is Equal. Cancers. 2022;14(3):627. DOI: https://doi.org/10.3390/cancers14030627.
15. Tourelle KM, Boutin S, Weigand MA, Schmitt FCF. The Association of Gut Microbiota and Complications in Gastrointestinal-Cancer Therapies. Biomedicines. 2021;9(10):1305. DOI: 10.3390/biomedicines9101305.
16. Ullah H, Arbab S, Tian Y, Chen Y, Liu CQ, Li Q, et al. Crosstalk between gut microbiota and host immune system and its response to traumatic injury. Front Immunol. 2024;15:1413485. DOI: 10.3389/fimmu.2024.1413485.
17. Wei L, Wen XS, Xian CJ. Chemotherapy-Induced Intestinal Microbiota Dysbiosis Impairs Mucosal Homeostasis by Modulating Toll-like Receptor Signaling Pathways. Int J Mol Sci. 2021;22(17):9474. DOI: 10.3390/ijms22179474.
18. DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current Understanding of Dysbiosis in Disease in Human and Animal Models. Inflamm Bowel Dis. 2016;22(5):1137-50. DOI: 10.1097/MIB.0000000000000750.
19. Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 2022;28(30):4053-4060. DOI: 10.3748/wjg.v28.i30.4053.
20. Li R, Li J, Zhou X. Lung microbiome: new insights into the pathogenesis of respiratory diseases. Sig Transduct Target Ther. 2024;9(1):19. DOI: https://doi.org/10.1038/s41392-023-01722-y.
21. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.J Clin Oncol. 2023;41(22):3867-3872. DOI: 10.1200/ JCO.22.02864.
22. Cheng J, Zhou L, Wang H. Symbiotic microbial communities in various locations of the lung cancer respiratory tract along with potential host immunological processes affected. Front. Cell. Infect. Microbiol. 2024;14:1296295. DOI: 10.3389/fcimb.2024.1296295.
23. Zhao Y, Liu Y, Li S, Peng Z, Liu X, Chen J, et sl. Role of lung and gut microbiota on lung cancer pathogenesis. J Cancer Res Clin Oncol. 2021;147(8):2177-2186. DOI: 10.1007/s00432-021-03644-0.
24. Weinberg F, Dickson RP, Nagrath D, Ramnath N. The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients? Cancers (Basel). 2020;13(1):13. DOI: 10.3390/cancers13010013.
25. Li KJ, Chen ZL, Huang Y, Zhang R, Luan XQ, Lei TT, et al. Dysbiosis of lower respiratory tract microbiome are associated with inflammation and microbial function variety. Respir Res. 2019;20(1):272. DOI: 10.1186/ s12931-019-1246-0.
26. Pizzo F, Maroccia Z, Hammarberg Ferri I, Fiorentini C. Role of the Microbiota in Lung Cancer: Insights on Prevention and Treatment. Int J Mol Sci. 2022;23(11):6138. DOI: 10.3390/ijms23116138.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 3, 174, 118-125 pages, index UDC 616-007-07:616.0.14

DOI:

10.29254/2077-4214-2024-3-174-118-125